The Influence of Mucinous Histology on the Prognosis of Stage II and III Colorectal Cancers.

IF 2.4 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
İsa Caner Aydin, Mehmet Torun, Mehmet Reşit Sönmez, Serkan Ademoğlu, Ahmet Orhan Sunar, Orhan Uzun, Selçuk Gülmez, Erdal Polat, Mustafa Duman
{"title":"The Influence of Mucinous Histology on the Prognosis of Stage II and III Colorectal Cancers.","authors":"İsa Caner Aydin, Mehmet Torun, Mehmet Reşit Sönmez, Serkan Ademoğlu, Ahmet Orhan Sunar, Orhan Uzun, Selçuk Gülmez, Erdal Polat, Mustafa Duman","doi":"10.3390/medicina61030456","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background and Objectives:</i> Mucinous adenocarcinoma (MAC) and mucinous components (MCP) in colorectal cancers (CRC) have shown conflicting results regarding their prognostic impact. This study aims to evaluate survival differences between MAC, MCP, and non-mucinous adenocarcinoma (nMAC) in stage II and III CRC patients. <i>Materials and Methods:</i> 224 CRC patients who underwent surgery between 2013 and 2021 were analyzed retrospectively. Patients were classified as nMAC, MCP, or MAC based on the percentage of extracellular mucin. Those who received neoadjuvant therapy, had stage I or IV TNM disease, and emergency cases were excluded. Survival analysis was performed using Kaplan-Meier curves and Cox regression models. <i>Results:</i> MAC patients showed worse survival outcomes compared to nMAC (<i>p</i> = 0.025). No difference in survival was found between MCP and nMAC (<i>p</i> = 0.055). Multivariate analysis identified MAC (OR: 2.814; <i>p</i> = 0.014) and perineural invasion (PNI) (OR: 2.283; <i>p</i> = 0.008) as independent factors associated with worse survival. Kaplan-Meier analysis revealed MAC's worse prognosis than nMAC (<i>p</i> = 0.027). <i>Conclusions:</i> MAC was shown to have a worse prognosis than nMAC in stage II and III CRC patients, while MCP survival rates were similar with nMAC. These findings suggest that MAC requires more careful treatment approaches, while MCP and nMAC have better survival rates. Further studies focusing on molecular and genetic profiles are needed to better understand these outcomes.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 3","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943597/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina-Lithuania","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/medicina61030456","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objectives: Mucinous adenocarcinoma (MAC) and mucinous components (MCP) in colorectal cancers (CRC) have shown conflicting results regarding their prognostic impact. This study aims to evaluate survival differences between MAC, MCP, and non-mucinous adenocarcinoma (nMAC) in stage II and III CRC patients. Materials and Methods: 224 CRC patients who underwent surgery between 2013 and 2021 were analyzed retrospectively. Patients were classified as nMAC, MCP, or MAC based on the percentage of extracellular mucin. Those who received neoadjuvant therapy, had stage I or IV TNM disease, and emergency cases were excluded. Survival analysis was performed using Kaplan-Meier curves and Cox regression models. Results: MAC patients showed worse survival outcomes compared to nMAC (p = 0.025). No difference in survival was found between MCP and nMAC (p = 0.055). Multivariate analysis identified MAC (OR: 2.814; p = 0.014) and perineural invasion (PNI) (OR: 2.283; p = 0.008) as independent factors associated with worse survival. Kaplan-Meier analysis revealed MAC's worse prognosis than nMAC (p = 0.027). Conclusions: MAC was shown to have a worse prognosis than nMAC in stage II and III CRC patients, while MCP survival rates were similar with nMAC. These findings suggest that MAC requires more careful treatment approaches, while MCP and nMAC have better survival rates. Further studies focusing on molecular and genetic profiles are needed to better understand these outcomes.

黏液组织学对II期和III期结直肠癌预后的影响。
背景和目的:结直肠癌(CRC)中的粘液腺癌(MAC)和粘液成分(MCP)在其预后影响方面显示出相互矛盾的结果。本研究旨在评估MAC、MCP和非粘液腺癌(nMAC)在II期和III期CRC患者中的生存差异。材料与方法:回顾性分析2013年至2021年接受手术治疗的224例结直肠癌患者。根据细胞外粘蛋白的百分比将患者分为nMAC、MCP或MAC。那些接受新辅助治疗,有I期或IV期TNM疾病和急诊病例被排除在外。生存率分析采用Kaplan-Meier曲线和Cox回归模型。结果:与nMAC患者相比,MAC患者的生存结果更差(p = 0.025)。MCP与nMAC的生存率无差异(p = 0.055)。多变量分析确定MAC (OR: 2.814;p = 0.014)和神经周围浸润(PNI) (OR: 2.283;P = 0.008)是与生存率较差相关的独立因素。Kaplan-Meier分析显示MAC预后较nMAC差(p = 0.027)。结论:在II期和III期CRC患者中,MAC的预后比nMAC差,而MCP的生存率与nMAC相似。这些发现表明,MAC需要更谨慎的治疗方法,而MCP和nMAC有更好的生存率。为了更好地理解这些结果,需要进一步研究分子和基因图谱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicina-Lithuania
Medicina-Lithuania 医学-医学:内科
CiteScore
3.30
自引率
3.80%
发文量
1578
审稿时长
25.04 days
期刊介绍: The journal’s main focus is on reviews as well as clinical and experimental investigations. The journal aims to advance knowledge related to problems in medicine in developing countries as well as developed economies, to disseminate research on global health, and to promote and foster prevention and treatment of diseases worldwide. MEDICINA publications cater to clinicians, diagnosticians and researchers, and serve as a forum to discuss the current status of health-related matters and their impact on a global and local scale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信